CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating ...

Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the ...

Protagonist Therapeutics (PTGX) announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, a mimetic of the natural hormone hepcidin, has ...

The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...